Nurix Therapeutics (NRIX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jeet ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics, a clinical-stage biopharmaceutical company pioneering long-acting oral therapies, today announced a strategic collaboration with Thermo ...

Carey says that the primary goal of the service is to “increase access to clinical pharmacy expertise for ... de-prescribing and finding the ideal therapeutics combination.

Our research in Clinical Pharmacy & Pharmacy Practice focuses on optimising ... and ensuring the safe and effective delivery of therapeutics. We work on nanoparticle-based drug delivery, long-acting ...

A phase 3 clinical trial application is aimed for submission in Q2 2021 for ARCT-021 to evaluate efficacy and safety. A key challenge for RNA-based therapeutics is handling the drug product from ...

The successful and safe delivery of therapeutics relies on understanding how easily drugs can pass through biological barriers which protect cells.

Throughout her career, Ms. Colacot has led quality functions across clinical ... of Pharmacy and an M.S. in Biomedical Engineering from the University of Alabama at Birmingham. Applied ...

Zevra to receive a 2025 New Treatment Award for MIPLYFFA™ at the 21st Annual WORLDSymposium Eight abstracts discussing data and clinical experience associated with MIPLYFFA accepted for poster ...

Mersana Therapeutics, Inc. recently disclosed encouraging updates in a Form 8-K report filed with the Securities and Exchange Commission. The company unveiled positive initial clinical data from ...

An investor who sued Verve Therapeutics Inc. for allegedly misleading investors about a clinical trial for its cholesterol medicine has voluntarily dismissed the proposed class action.

To advance the profession of pharmacy, foster an environment that values employee contributions, and support development through balance and accountability. To have fun, recognize our accomplishments, ...

the biotech startup Tune Therapeutics announced a major milestone Sunday — raising $175 million in a Series B funding round to support its first clinical trial. Tune has developed a novel ...